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Overproduction of cortisol by the hypothalamus–pituitary–adrenal hormone system results in the clinical disorder known as Cushing’s syndrome.
Genomics studies have identified a key mutation (L205R) in the a-isoform
of the catalytic subunit of cAMP-dependent protein kinase (PKACa) in
adrenal adenomas of patients with adrenocorticotropic hormone-independent Cushing’s syndrome. Here, we conducted kinetics and inhibition studies on the L205R-PKACa mutant. We have found that the L205R
mutation affects the kinetics of both Kemptide and ATP as substrates,
decreasing the catalytic efficiency (kcat/KM) for each substrate by 12-fold
and 4.5-fold, respectively. We have also determined the IC50 and Ki for the
peptide substrate-competitive inhibitor PKI(5–24) and the ATP-competitive
inhibitor H89. The L205R mutation had no effect on the potency of H89,
but causes a > 250-fold loss in potency for PKI(5–24). Collectively, these
data provide insights for the development of L205R-PKACa inhibitors as
potential therapeutics.

doi:10.1002/2211-5463.12396

Cushing’s syndrome is a clinical disorder caused by
the overproduction of cortisol by the hypothalamus–
pituitary–adrenal hormone system [1]. Symptoms of
Cushing’s syndrome include central obesity, buffalo
hump, moon face, and striae, which together form a
metabolic syndrome that can cause or worsen the
effects of hypertension, heart disease, and diabetes,
and lead to morbidity and mortality [1]. Pathophysiologically, Cushing’s syndrome can be caused by pituitary adenomas that release unregulated amounts of
ACTH hormone (ACTH-dependent Cushing’s syndrome), adrenal adenomas that release unregulated

amounts of cortisol directly (ACTH-independent
Cushing’s syndrome), and ectopic tumors outside the
hypothalamus–pituitary–adrenal axis that produce
ACTH [1].
Recent genomics studies of patients with ACTHindependent Cushing’s syndrome revealed that ~ 40%
of the adrenal adenomas from these patients carried a
T617G mutation in the PRKACA gene, which encodes
for the a-isoform of the catalytic subunit of cAMPdependent protein kinase (PKACa) [2–5]. Under
normal physiological conditions, the ACTH peptide
hormone binds to and activates the melanocortin 2

Abbreviations
ACTH, adrenocorticotropic hormone; H89, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide; Kemptide, the PKACa peptide
substrate with the sequence H2N-Leu-Arg-Arg-Ala-Ser-Leu-Gly-OH; MAB, methyl aminobutyric acid; MC2R, melanocortin 2 G-protein-coupled
receptor; PKACa, a-isoform of the catalytic subunit of cAMP-dependent protein kinase; PKI(5–24), cAMP-dependent protein kinase inhibitor,
residues 5–24; PRKACA, gene encoding cAMP-dependent protein kinase catalytic subunit alpha; Rh, rhodamine B.
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receptor (MC2R) in the adrenal cortex; MC2R is a
Gs-coupled receptor that, when activated, elevates
cAMP levels and activates PKACa [6]. The somatic
mutation in the PRKACA gene results in the expression of a mutant form of PKACa, where Leu205 has
been mutated to Arg. The L205R-PKACa mutation
leads to loss of binding of the PKA regulatory subunits (PKARIa/b and PKARIIa/b) [2,3,5,7,8], loss of
sensitivity to cAMP signaling [2,5,7], constitutive activation of the mutant PKACa protein [2,4,5], and
unregulated phosphorylation of PKACa substrates
[3–5], presumably including those involved in downstream cortisol biosynthesis.
Structural biology has given some insights as to how
the single-point mutation causes the disruption in
PKACa regulation. In the wt-PKACa cocrystal structure with the PKI(5–24) inhibitor peptide and ATP
[9,10], Leu205 is part of a group of hydrophobic residues (Leu198, Gly200, Pro202, and Leu205) that form
the P+1-binding pocket (Fig. 1A), an important site
for substrate, regulatory subunit, and inhibitor recognition. The hydrophobic side chain of Ile22 of PKI(5–24)
binds in the P+1-binding site, creating a positive binding interaction and contributing to overall inhibitor
binding. In the cocrystal structure of the L205RPKACa mutant with PKI(5–24) and ATP (Fig. 1B)
[10], the mutation of Leu205 to Arg results in the larger
Arg205 residue occupying the P + 1 pocket (now
defined as Leu198, Gly200, Pro202, and Arg205), the
binding pocket normally occupied by Ile22 of PKI. The
L205R mutation prevents Ile22 of PKI from binding in
the P + 1 pocket and causes a change in binding conformation of the C-terminal end of PKI(5–24). The mutant
structure offers an explanation for the lack of binding
by the regulatory subunits and predicts a lack of inhibition of L205R-PKACa by PKI, as both of these require
a hydrophobic binding interaction in the P + 1 pocket
of wt-PKACa for regulation or inhibition.
While the structure of the L205R-PKACa mutant
[10] and the overall effects of the mutation in a cellular
environment [2–5,7,8] have been reported, detailed
studies of the enzymology of the mutant have not. Measurement of the specific activity of the L205R-PKACa
mutant from cell lysates [2,4,5,7] and purified recombinant protein production [10] have been reported, but a
full analysis of the kinetics parameters has not been
performed. In addition, the sensitivity of the L205RPKACa mutant to known wt-PKACa inhibitors has
been measured in cell lysates at fixed inhibitor concentrations [4,5], but a study to determine how the L205R
mutation affects the IC50 and Ki of these inhibitors has
not been carried out. Here, we report a kinetics and
inhibition study to fully characterize the enzymology of

L205R-PKACa kinetics and inhibition

Fig. 1. Crystal structures of wt-PKACa (A) and L205R-PKACa (B).
(A) Crystal structure of wt-PKACa (Cyan) and PKI (Yellow) with
P + 1 pocket residues shown as space-filling models (PDBID:
4WB5). (B) Crystal structure of L205R-PKACa (Green) and PKI
(Magenta) with P + 1 pocket residues shown as space-filling
models (PDBID: 4WB6). For each structure, P + 1 pocket residues
are colored the same as PKI.

the L205R-PKACa mutant and determine the effect of
the mutation on enzyme function. These studies are
an important first step toward investigating L205RPKACa as a therapeutic molecular target for the treatment of ACTH-independent Cushing’s syndrome.

Materials and methods
Reagents
All assay reagents, including buffer salts, ATP, and MgCl2,
were of molecular biology grade and purchased from
Sigma-Aldrich (St. Louis, MO, USA). H89 was purchased
from Selleck Chem (Houston, TX, USA). PKI(5–24) was
purchased from Alfa Aesar (Tewksbury, MA, USA).
HPLC-grade solvents were purchased from VWR (Radnor,
PA, USA).
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Production of recombinant PKACa kinases
The plasmid for the expression of recombinant human
L205R-PKACa was prepared by GenScript (Piscataway,
NJ, USA) using a combination of gene synthesis and
molecular biology (see Fig. S1 for gene insert sequence, full
plasmid sequence, and resulting protein sequence). First, a
protein sequence for full-length recombinant L205RPKACa (Gly1 to Phe350) was designed to include an Nterminal (His)6 tag followed immediately by a TEV cleavage site (ENLYFQ/G), where the remaining glycine residue
left after TEV cleavage became the first glycine in the processed protein sequence. To the codons for this sequence
(based on human PRKACA gene with T617G mutation)
were added a 50 -NdeI restriction site (which includes a start
codon), two stop codons, and a 30 -HindIII restriction site.
This entire gene insert was synthesized, cloned into the
pET-17b vector, and the vector sequenced to confirm the
correct incorporation of the insert. To express L205RPKACa, BL21(DE3)-competent Escherichia coli cells were
transformed with the plasmid described above, selecting
with ampicillin (50 mgL1). Bacterial cells were grown in
autoinduction media at 37 °C for 16 h. Following growth,
cells were spun down to a pellet at 9000 g for 10 min, lysed
by a single pass through an Avestin Emulsiflex (Avestin,
Ottawa, ON, Canada) homogenizer operating at 25 000 psi
into buffer (25 mM Tris/HCl (pH 8), 300 mM NaCl, and
10 mM imidazole), allowed to equilibrate for 30 min at
ambient temperature, and debris removed by centrifugation
at 48 000 g for 30 min. The soluble fraction was then
loaded onto a Ni-NTA column and washed with 5 column
volumes of the loading buffer, and pure (His)6-L205RPKACa was eluted with 100 mM imidazole. The purified
protein was then treated with TEV protease (1 wt%; 1 mg
TEV protease per 100 mg L205R-PKACa) overnight at
room temperature to remove the (His)6 tag. Following
TEV cleavage, the kinase was dialyzed into storage buffer
(25 mM sodium phosphate buffer with 10% glycerol and
1 mM DTT), aliquoted, and stored at 80 °C until use. To
verify that the recombinant kinase protein contains the
L205R point mutation, a trypsin digest was performed and
the fragments analyzed LC/MS/MS experiment using direct
injection on a LCQ DecaXP Max mass spectrometer
(ThermoScientific, Waltham, MA, USA). The fragment
containing R205 was identified (195TWTLCGTPEYR205,
calculated: 1327.49 Da; found: 1327.16 Da), confirming
installation of the mutation. wt-PKACa was produced and
purified as previously reported [11] in parallel with the
L205R-PKACa mutant.

Kinetics assay
Kinetics assays were performed using an HPLC-Vis assay
with a rhodamine-labeled Kemptide analogue (Rh-MABKemptide), which we have reported elsewhere [11]. Assays

608

were performed in 96-well plates at 25 °C with a total reaction volume of 200 lL. For determination of kinetics
parameters for Kemptide peptide substrate, kinase reactions contained L205R-PKACa (2 nM), ATP (1 mM),
MgCl2 (10 mM), and Rh-MAB-Kemptide (200–12.5 lM,
twofold dilutions) in 50 mM MOPS (pH 7.4, adjusted with
NaOH). Reactions were initiated by the addition of the
Rh-MAB-Kemptide analogue, run for 15 min, and then
quenched with 5% phosphoric acid (100 lL). For determination of kinetics parameters for ATP, kinase reactions
contained L205R-PKACa (4 nM), Rh-MAB-Kemptide
(25 lM), MgCl2 (10 mM), and ATP (400–6.25 lM, twofold
dilutions) in 50 mM MOPS (pH 7.4, adjusted with NaOH).
Reactions were initiated by the addition of ATP, run for
15 min, and then quenched with 5% phosphoric acid
(100 lL). Negative controls that consisted of kinase reactions where buffer was added in place of active kinase
enzyme were included in all assay runs. All kinase reactions
were carried out in triplicate for each concentration of RhMAB-Kemptide or ATP. The 96-well plate was then loaded
into the HPLC autosampler (Agilent, Santa Clara, CA,
USA), and each kinase reaction analyzed by the HPLC
method described below. The volume of the injection was
varied from 5 to 100 lL such that 0.5 nmoles of chromophore-labeled peptide was loaded and analyzed for each
kinase reaction. Following HPLC analysis, the % phosphorylation was determined for each Rh-MAB-Kemptide or
ATP concentration by integrating the area of the peaks for
the substrate and product at 560 nm. % Phosphorylation
data were converted to velocities and plotted against the
concentrations of the substrate. Under the kinase reaction
conditions above, product conversions were ≤11% at substrate concentrations equal to KM, ensuring that the experiments were run under initial velocity conditions. Curve
fitting and the determination of kinetics parameters were
performed in PRISM 7 (GraphPad, La Jolla, CA, USA)
using nonlinear regression to the Michaelis–Menten equation. Three experimental replicates were carried out for
each curve, and the mean and SEM for each kinetic parameter were determined. For comparison, wt-PKACa replicates were performed in parallel on the same 96-well plates
with technical and experimental replicates for the L205R
mutant as reported elsewhere [11].

Inhibition assay
Inhibition assays were performed in 96-well plates at 25 °C
with a total reaction volume of 200 lL. Kinase reactions
contained L205R-PKACa (4 nM), ATP (25 lM), MgCl2
(10 mM), Rh-MAB-Kemptide (30 lM), inhibitor (H89,
16 lM–0.015 nM or PKI(5–24), 62.5 lM–0.24 nM; fourfold
dilutions) in 50 mM MOPS (pH 7.4, adjusted with NaOH).
For H89, reactions were initiated by the addition of ATP
after a 10-min preincubation of inhibitor with L205RPKACa and the other reaction components. For PKI(5–24),
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reactions were initiated by the addition of Rh-MAB-Kemptide
after a 10-min preincubation of inhibitor with L205R-PKACa
and the other reaction components. Reactions were run for
40 min and then quenched with 5% phosphoric acid
(100 lL). Kinase reactions were carried out in duplicate for
each concentration of each inhibitor. Negative controls that
consisted of kinase reactions where buffer was added in
place of inhibitor were included in all assay runs. The 96well plate was then loaded into the HPLC autosampler and
each kinase reaction analyzed by the HPLC method
described below (80 lL injection volume, 0.5 nmoles of
chromophore-labeled peptide). Following HPLC analysis,
the % phosphorylation was determined for each inhibitor
concentration by integrating the area of the peaks for the
substrate and product at 560 nm. % Phosphorylation data
were normalized to the control well without inhibitor,
converted to % inhibition, and plotted against the log of
the concentrations of the inhibitor. Curve fitting and the
determination of the IC50 were performed in PRISM 7
(GraphPad) using nonlinear regression to the four-parameter log(inhibitor) versus response equation. Ki’s were
calculated using the Cheng–Prusoff equation and the KM
for Rh-MAB-Kemptide or ATP with L205R-PKACa
(Table 1). Three experimental replicates were carried out
for each curve, and the mean and SEM for the IC50 and
Ki for each inhibitor were determined. For comparison,
wt-PKACa replicates were performed in parallel on the
same 96-well plates with technical and experimental replicates for the L205R mutant as reported elsewhere [11].

HPLC assay method
All HPLC experiments were carried out on an Agilent LC
1200 system with a degasser, quaternary pump, vial and
well plate autosampler, column heater, and diode array

Table 1. Kinetics parameters for the L205R-PKACa mutant.

L205R-PKACa
Rh-MAB-Kemptide
KM (lM)
Vmax (lmolmin1mg1)
kcat (min1)
kcat/KM (lM1min1)
ATP
KM (lM)
Vmax (lmolmin1mg1)
kcat (min1)
kcat/KM (lM1min1)
a

wt-PKACaa

Fold
changeb

60.9
11.2
450
7.38






8.4
1.7
70
0.52

9.74
21.7
870
90.7






0.88
3.4
138
22.7

+6.3
1.9
1.9
12.3

27.6
3.23
129
4.76






4.5
0.52
21
1.09

16.9
9.04
362
21.4






1.3
0.65
26
1.2

+1.6
2.8
2.8
4.5

Kinetics data from Reference [11]. b Positive (+) fold changes represent an increase in the value of the kinetics parameter for the
L205R-PKACa mutant relative to wt-PKACa; negative () fold
changes represent a decrease in the value of the kinetics parameter for the L205R-PKACa mutant relative to wt-PKACa.

detector. All data were collected and processed with Agilent
software. In all HPLC runs, absorbance was
monitored at 560, 550, 280, and 210 nm. For kinetics and
inhibition assays, the system was operated in analytical
mode using a Restek Ultra C18 3 lm, 2.1 9 100 mm column and a flow rate of 0.3 mLmin1. Assays were analyzed using a gradient of water with 0.1% formic acid
(Solvent A) and acetonitrile with 0.1% formic acid (Solvent
B); gradient: 0–0.5 min, 5% B; 0.5–9.0 min, 5–77% B; 9.0–
9.5 min, 77% B; 9.5–10 min, 77–5% B; 10–13 min, 5% B.
% Phosphorylation was determined by integrating both the
substrate and product peaks measured at 560 nm.
CHEMSTATION

Results
Expression and purification of the L205R-PKACa
mutant
We began our work by designing and synthesizing
plasmids for the expression of L205R-PKACa using a
combination of gene synthesis and molecular biology.
Our expression plasmids each included an N-terminal
(His)6 tag for purification followed by a TEV cleavage
site blunt against the first residue of the kinase. In our
initial plasmid, we optimized the codons for the
PRKACA gene, including the T617G mutation, for
expression in E. coli (data not shown). However, upon
growing cultures for protein production with this
codon-optimized plasmid, we observed that bacterial
growth was significantly impaired compared to bacterial growth in previous protein production of wtPKACa using a non-codon-optimized plasmid [12].
We hypothesized that expression of large amounts of
L205R-PKACa from use of the codon-optimized plasmid might be resulting in toxicity to the bacteria. To
address this issue, we prepared a second plasmid of
the same design, but with endogenous human codons
for PRKACA and the observed T617G mutation (see
Materials and methods and Fig. S1). With this plasmid, bacterial growth in protein production was
restored to expected levels. Following lysis, purification, and cleavage with TEV protease, we were able to
produce the L205R-PKACa mutant in quantities of
~ 5 mgmL1 of culture.
Kinetics studies
With L205R-PKACa protein in hand, we next turned
to studying the kinetics of the mutant kinase with
Kemptide peptide substrate and ATP. For the kinetics
work, we utilized an HPLC-Vis endpoint assay with a
rhodamine B-labeled Kemptide analogue (Rh-MABKemptide), which we have reported elsewhere [11].

FEBS Open Bio 8 (2018) 606–613 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

609

N. M. Luzi et al.

L205R-PKACa kinetics and inhibition

Fig. 2. Kinetic analysis of the phosphorylation of Rh-MABKemptide by the L205R-PKACa mutant at a fixed concentration of
ATP for determination of KM,Kemptide and other kinetic parameters.
Similar data for wt-PKACa can be found in reference [11]. The
range of values on the graph axes for the kinetics analysis of RhMAB-Kemptide (this figure) and ATP (Fig. 3) are different.

This assay separates and directly quantifies both substrate and phosphorylated product.
To determine the effect of the mutation on kinetics
with Kemptide, we first ran a series of kinase reactions
with varying concentrations of Rh-MAB-Kemptide at
a fixed concentration of ATP, in order to determine
the kinetic parameters for Kemptide (see Materials
and methods). Following kinase reactions, percent
phosphorylation data were transformed to velocities,
and the kinetics parameters were determined by fitting
the data to the Michaelis–Menten equation (Fig. 2,
Table 1). The KM,Kemptide for the L205R-PKACa
mutant (60.9  8.4 lM) was found to be ~ 6-fold
higher than the KM,Kemptide for wt-PKACa
(9.74  0.88 lM), likely due to impaired binding of the
hydrophobic Leu6 residue in Kemptide to the mutated
P + 1 biding site in L205R-PKACa, resulting in a
lower binding affinity of Kemptide for the mutant versus wt-PKACa. Both the Vmax,Kemptide (11.2  1.7
lmolmin1mg1) and the kcat,Kemptide (450  70
min1) for the mutant were found to be ~ 2-fold lower
than Vmax,Kemptide (21.7  3.4 lmolmin1mg1) and
the kcat,Kemptide (870  138 min1) for wt-PKACa,
demonstrating that the mutation slows the overall
phosphotransfer chemical reaction. Determination of
kcat/KM for Kemptide with the L205R-mutant
(7.38  0.52 lM1min1) shows that the catalytic efficiency of the mutant is ~ 12-fold lower than the kcat/
KM for Kemptide with wt-PKACa (90.7  22.7
lM1min1), demonstrating that the L205R mutant
has a significantly lower specificity for Kemptide than
the wild-type kinase.
We next turned to determining whether the L205R
mutation, which occurs in the peptide substrate-binding site, has any effect on ATP kinetics (Fig. 3, Table
1). With ATP as a substrate, we observed the same
610

Fig. 3. Kinetic analysis of the phosphorylation of Rh-MABKemptide by the L205R-PKACa mutant at varying ATP
concentrations for determination of KM,ATP and other kinetic
parameters. Similar data for wt-PKACa can be found in reference
[11]. The range of values on the graph axes for the kinetics
analysis of Rh-MAB-Kemptide (Fig. 2) and ATP (this figure) are
different.

trends that are seen in the Kemptide kinetic parameters, but with a lower magnitude of the effect. The
for
the
L205R-PKACa
mutant
KM,ATP
(27.6  4.5 lM) was found to be higher than the KM,
ATP for wt-PKACa (16.9  1.3 lM), but only by a factor
of
~ 1.6-fold.
Both
the
Vmax,ATP
(3.23  0.52 lmolmin1mg1) and the kcat,ATP
(129  21 min1) for the mutant were found to be
lower than Vmax,ATP (9.04  0.33 lmolmin1mg1)
and the kcat,ATP (362  26 min1) for wt-PKACa by
2.8-fold. Finally, the kcat/KM for ATP with the L205Rmutant (4.76  1.09 lM1min1) was found to be
lower than the kcat/KM for ATP with wt-PKACa
(21.4  1.2 lM1min1) by a factor of 4.5-fold.
Collectively, these data demonstrate that the L205R
mutation has effects on all of the kinetics parameters,
especially the catalytic efficiency (kcat/KM), for both
Kemptide and ATP despite the fact that the point mutation only occurs in the peptide substrate-binding site.
Inhibition studies
Having characterized the kinetics of the L205R mutant
with both peptide substrate and ATP, we turned to
determining the sensitivity of the L205R mutant to
known wt-PKACa inhibitors. We first determined the
ability of the peptide substrate-competitive inhibitor
PKI(5–24) to inhibit the phosphotransferase function
of the L205R mutant (Fig. 4) in our HPLC-Vis inhibition assay. As seen in Table 2, the single L205R point
mutation has a significant effect on inhibition by PKI
(5–24). The IC50 (1870  206 nM) and Ki (1250 
138 nM) of PKI(5–24) with the L205R mutant were
both found to be > 250-fold higher than the IC50
(7.4  1.2 nM) and Ki (3.7  0.6 nM) for wt-PKACa.

FEBS Open Bio 8 (2018) 606–613 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
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Fig. 4. Inhibition of wt-PKACa (black circles) and the L205R-PKACa
mutant (red triangles) by PKI(5–24). The inhibitor concentration
ranges for PKI(5–24) (this figure) and H89 (Fig. 5) are different.

Table 2. Data for inhibition of the L205R-PKACa mutant by wtPKACa inhibitors.
L205R-PKACa
PKI(5–24)c
IC50 (nM)
Ki (nM)d
H89
IC50 (nM)
Ki (nM)d

wt-PKACaa

Fold changeb

1870  206
1250  138

7.4  1.2
3.7  0.6

253
338

60.6  8.4
27.8  5.7

63.3  4.5
25.5  1.8

0.96
1.1

a

Inhibition data from Reference [11]. bFold changes represent the
change in the value of the inhibition parameter for the L205RPKACa mutant relative to wt-PKACa. cSequence for PKI(5–24):
H2N-TTYADFIASGRTGRRNAIHD-COOH. dKi’s were calculated
using Cheng–Prusoff equation and the KM’s from Table 1.

This is a remarkable decrease in inhibition of the
mutant by the simple disruption of binding of one of
the twenty amino acids of the inhibitor and underscores
the importance of binding to the P+1-binding pocket
for potent inhibition. We then determined the ability of
the ATP-competitive inhibitor H89 to inhibit the
mutant (Fig. 5). Unlike PKI(5–24), the L205R mutation
seems to have no effect on inhibition of phosphotransferase function by H89. The IC50 (60.6  8.4 nM) and
Ki (27.8  5.7 nM) for H89 with the L205R mutant
were effectively identical to the IC50 (63.3  4.5 nM)
and Ki (25.5  1.8 nM) with wt-PKACa (Table 2).

Discussion
This work reports the first study that determines the
fundamental kinetics parameters for the L205RPKACa mutant kinase with both Kemptide and ATP
substrates. We have found that the KM,Kemptide for the
L205R-PKACa mutant is ~ 6-fold higher than for wtPKACa. KM is generally regarded as a measure of the
affinity (Kd) of a substrate for the enzyme; this is an
assumption, however, as the expression for KM

Fig. 5. Inhibition of wt-PKACa (black circles) and the L205R-PKACa
mutant (red triangles) by H89. The inhibitor concentration ranges
for PKI(5–24) (Fig. 4) and H89 (this figure) are different.

[(k1 + k2)/k1] contains both the Kd and the first-order
rate constant for conversion of the [E][S] complex to
product. In this case, the increase in KM indicates that
the L205R mutation in the P+1-binding pocket of the
mutant leads to an ~ 6-fold loss in affinity, due to the
loss of the productive binding interaction of residue
Leu6 of Kemptide with the P + 1 pocket. The turnover number for the Kemptide substrate (kcat,Kemptide)
was found to be lower for the L205R mutant than for
wt-PKACa by ~ 2-fold, showing that the rate of catalysis for the mutant is impaired. Previous work with
the L205R-PKACa mutant by Lee and coworkers
using live-cell FRET also showed a reduced catalytic
activity with an AKAR4 reporter protein [8], presumably due to loss of the key binding interaction between
Leu476 of AKAR4 with the P + 1 pocket of the
L205R mutant. Finally, an examination of kcat/KM for
Kemptide with the mutant and wt-PKACa shows a
> 12-fold decrease in the catalytic efficiency. In this
case, the decrease in the affinity (KM,Kemptide) and the
turnover number (kcat,Kemptide) appear to reinforce
each other, leading to the large decrease in kcat/KM for
Kemptide. The catalytic efficiency reflects the specificity of each enzyme for Kemptide and shows that the
L205R mutation leads to the > 12-fold decrease in
specificity versus wt-PKACa. This is in agreement with
recent work by Schwartz and coworkers, demonstrating that the L205R mutation changes the substrate
specificity of the kinase and that the L205R mutant
more readily phosphorylates substrates with acidic
residues in the P + 1 position [13]. The catalytic efficiency can also be viewed as the second-order rate
constant and the probability that the [E][S] complex
will be converted to product. These data support a
model for the L205R-PKACA mutant where the
[E][S] complex is either dissociating faster than it is
being converted to product or that if it is converted to
product, catalysis is slower. Our work, taken together
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with that of Lee [8] and Schwartz [13], also suggests that
the L205R-PKACa mutation causes ACTH-independent
Cushing’s syndrome through a change of substrate
specificity and not simply constitutive activation of the
L205R gain-of-function mutant kinase. This change in
substrate specificity for the L205R mutant is the result
of both a decrease in phosphorylation of wt-PKAa substrates and an increase in the phosphorylation of new,
alternative substrates for the L205R mutant.
Surprisingly, the kinetics analysis also shows that the
L205R mutation affects the kinetics of the ATP substrate, even though the structural biology data [10]
show no conformational change in this binding pocket.
Our kinetics data clearly indicate that there is communication between the ATP-binding site and the peptide
substrate-binding site, as the L205R mutation does
affect ATP kinetics. We found that the KM,ATP for the
L205R-PKACa mutant was ~ 1.6-fold higher than for
wt-PKACa. Again, while KM is generally viewed as a
measure of affinity (Kd), this is an assumption as the
expression for KM [(k1 + k2)/k1] contains both the Kd
and the first-order rate constant for conversion of the
[E][S] complex to product. As it is unlikely that the
affinity of ATP for the binding site of the L205R
mutant has changed (based on the structural biology
data and our H89 inhibition data), the increase in KM,
ATP is likely the result of decreased catalysis by the
mutant due to a decrease in the binding of the Kemptide substrate. The turnover number data support this,
as the kcat,ATP for the L205R mutant was ~ 2.8-fold
lower than for wt-PKACa. However, without additional data on the microscopic rate constants k1, k1,
and k2, we cannot determine whether kcat,ATP = k2 and
the exact cause of the decrease in KM,ATP. For ATP, we
again see that the increase in the KM,ATP and decrease
in kcat,ATP appear to reinforce each other, leading to a
4.5-fold decrease in kcat/KM for ATP. Similar to the
results with Kemptide, this decrease in kcat/KM for ATP
supports a model for the L205R-PKACA mutant where
the [E][S] complex is either dissociating faster than it is
being converted to product or that if it is converted to
product, catalysis is slower. We cannot, however, rule
out that the L205R mutation slows catalysis by affecting the known rate-limiting step of ADP dissociation
[14]; additional experimental data would be needed to
examine that hypothesis.
Here, we also report the first studies on the susceptibility of the L205R-PKACa mutant to known inhibitors of wt-PKACa that determine the fundamental
inhibition parameters of IC50 and Ki. The L205R
mutation has a profound effect on inhibition of the
mutant by PKI(5–24), a peptide substrate-competitive
inhibitor (see Table 2 for sequence), with the IC50
612

increasing by > 250-fold and the Ki increasing by
> 330-fold. While it is not surprising that the L205R
mutation disrupts the binding of PKI(5–24), the loss
of potency was larger than we anticipated. We had
expected inhibition of L205R-PKACa with PKI(5–24)
to have a Ki similar to the inhibition of wt-PKACa
with the I22G-PKI(5–22) inhibitor (Ki = 470 nM)
reported by Walsh and coworkers [15]. In the I22GPKI(5–22) inhibitor, Ile22 (which binds in the P+1binding site) is replaced by Gly and this inhibitor loses
the binding affinity from the interaction of the
hydrophobic Ile22 side chain with the P + 1 pocket.
However, our data for the L205R-PKACa mutant
with PKI(5–24) suggest that the loss of potency may
come from more than just loss of the hydrophobic
binding interaction in the P + 1 pocket and that there
may be some repulsive interactions between the positively charged R205 and the positively charged H23
residue of the C terminus of the PKI(5–24) inhibitor.
The ATP-competitive inhibitor H89, however, displayed
nearly identical inhibition of both L205R-PKACa and
wt-PKACa, as expected from the structural similarity of
the ATP-binding pockets in the crystal structures [10].
The inhibition data that we report here for the L205R
mutant have profound implications for the design and
development of selective inhibitors of the mutant as
potential therapeutics. The standard approach for
developing pharmacological inhibitors for kinases in
both industry and academia is to use ATP-competitive
small molecules [16]. Our finding that the ATP-competitive inhibitor H89 has equal potency against both the
mutant and wt-PKACa will likely prevent the use of
this approach. Any inhibitor for therapeutic use
against the mutant will have to be selective for the
mutant over wt-PKACa, in order to not suffer from
off-target toxicity associated with wt-PKACa inhibition. wt-PKACa is the primary intracellular signaling
kinase for over 75 different G-protein-coupled receptors [6] and any potential inhibitor of the L205R
mutant that also inhibits wt-PKACa will likely cause
off-target effects in multiple organ systems and signaling pathways. The previously reported crystallography
data for the L205R-PKACa mutant [10] also support
that there will be poor selectivity between wt- and
L205R-PKACa, as the ATP-binding pockets of both
enzymes have an identical sequence and, at least in the
static crystal form, no conformational differences are
seen between wt- and L205R-PKACa. It is possible
that a type II kinase inhibitor, which flips the DFG
motif into the inactive conformation, could be developed to target the L205R mutant. However, it is
unclear whether a type II inhibitor could selectively
bind to the mutant over wt-PKACa. The L205R

FEBS Open Bio 8 (2018) 606–613 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

N. M. Luzi et al.

mutation occurs in the peptide substrate-binding site,
and it is likely that a successful mutant-selective inhibitor will need to be targeted to that binding site.

Acknowledgements
This research was supported in part by the VCU
School of Pharmacy (to KCE). Protein production
and purification were performed using facilities of the
VCU Massey Cancer Center Biological Macromolecule
Shared Resource (MCC-BMSR). LC/MS/MS was performed using the Massey Cancer Center Proteomics
Resource (MCC-PR). The MCC-BMSR and MCC-PR
are both supported with funding from NIH-NCI Cancer Center Support Grant 5P30CA16059-35.

Author contributions
KCE conceived and designed the study. KCE designed
the expression plasmid for the recombinant L205R
protein. NML and DLP expressed and purified the
recombinant L205R protein. CEL performed the trypsin digest and mass spectrometry experiment. NML
performed the kinetics and inhibition assays. NML
and KCE conducted the data analysis. KCE and
NML wrote and edited the manuscript. All authors
reviewed the results and approved the final version of
the manuscript.

References
1 van der Pas R, de Herder WW, Hofland LJ and
Feelders RA (2012) New developments in the medical
treatment of Cushing’s syndrome. Endocr Relat Cancer
19, R205–R223.
2 Beuschlein F, Fassnacht M, Assie G, Calebiro D,
Stratakis CA, Osswald A, Ronchi CL, Wieland T,
Sbiera S, Faucz FR et al. (2014) Constitutive activation
of PKA catalytic subunit in adrenal Cushing’s
syndrome. N Engl J Med 370, 1019–1028.
3 Goh G, Scholl UI, Healy JM, Choi M, Prasad ML,
Nelson-Williams C, Kunstman JW, Korah R, Suttorp
A-C, Dietrich D et al. (2014) Recurrent activating
mutation in PRKACA in cortisol-producing adrenal
tumors. Nat Genet 46, 613–617.
4 Cao Y, He M, Gao Z, Peng Y, Li Y, Li L, Zhou W, Li
X, Zhong X, Lei Y et al. (2014) Activating hotspot
L205R mutation in PRKACA and adrenal Cushing’s
syndrome. Science 344, 913–917.
5 Sato Y, Maekawa S, Ishii R, Sanada M, Morikawa T,
Shiraishi Y, Yoshida K, Nagata Y, Sato-Otsubo A,
Yoshizato T et al. (2014) Recurrent somatic mutations
underlie corticotropin-independent Cushing’s syndrome.
Science 344, 917–920.

L205R-PKACa kinetics and inhibition

6 Wettschureck N and Offermanns S (2005) Mammalian
G proteins and their cell type specific functions. Physiol
Rev 85, 1159–1204.
7 Calebiro D, Hannawacker A, Lyga S, Bathon K, Zabel
U, Ronchi C, Beuschlein F, Reincke M, Lorenz K,
Allolio B et al. (2014) PKA catalytic subunit mutations
in adrenocortical Cushing’s adenoma impair association
with the regulatory subunit. Nat Commun 5, 5680.
8 Lee S-R, Sang L and Yue DT (2016) Uncovering
aberrant Mutant PKA function with flow cytometric
FRET. Cell Rep 14, 3019–3029.
9 Knighton DR, Zheng J, Eyck LFT, Xuong N-H,
Taylor SS and Sowadski JM (1991) Structure of a
peptide inhibitor bound to the catalytic subunit of
cyclic adenosine monophosphate-dependent protein
kinase. Science 253, 414–420.
10 Cheung J, Ginter C, Cassidy M, Franklin MC,
Rudolph MJ, Robine N, Darnell RB and Hendrickson
WA (2015) Structural insights into mis-regulation of
protein kinase A in human tumors. Proc Natl Acad Sci
USA 112, 1374–1379.
11 Luzi NM, Lyons CE, Peterson DL and Ellis KC (2017)
Characterization of PKACa enzyme kinetics and
inhibition in an HPLC assay with a chromophoric
substrate. Anal Biochem 532, 45–52.
12 Coover RA, Luzi NM, Korwar S, Casile ME, Lyons
CE, Peterson DL and Ellis KC (2016) Design,
synthesis, and in vitro evaluation of a fluorescently
labeled irreversible inhibitor of the catalytic subunit of
cAMP-dependent protein kinase (PKACa). Org Biomol
Chem 14, 4576–4581.
13 Lubner JM, Dodge-Kafka KL, Carlson CR, Church
GM, Chou MF and Schwartz D (2017) Cushing’s
syndrome mutant PKAL205R exhibits altered substrate
specificity. FEBS Lett 591, 459–467.
14 Zhou J and Adams JA (1997) Participation of ADP
dissociation in the rate-determining step in cAMPdependent protein kinase. Biochemistry 36, 15733–
15738.
15 Glass DB, Cheng HC, Mende-Mueller L, Reed J and
Walsh DA (1989) Primary structural determinants
essential for potent inhibition of cAMP-dependent
protein kinase by inhibitory peptides corresponding to
the active portion of the heat-stable inhibitor protein. J
Biol Chem 264, 8802–8810.
16 Wu P, Nielsen TE and Clausen MH (2016) Smallmolecule kinase inhibitors: an analysis of FDAapproved drugs. Drug Discovery Today 21, 5–10.

Supporting information
Additional Supporting Information may be found
online in the supporting information tab for this article:
Fig. S1. Recombinant plasmid constructed for L205RPKACa.

FEBS Open Bio 8 (2018) 606–613 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

613

